Constellation Pharmaceuticals
As of the edition of 20 October 2026, Constellation Pharmaceuticals runs 2 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Constellation Pharmaceuticals was acquired in 2021; successor MORPHOSYS AG.
- Constellation Pharmaceuticals: acquired in 2021; successor MORPHOSYS AG
Drugs by status
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Total | 2 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| EZH2 Histone-lysine N-methyltransferase EZH2 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Constellation Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 7 trials led
- Blood and lymph: 5 trials led
- Immune system: 3 trials led